Annual report
4507.TEDINET S100VZCM
Period2024-04-01 → 2025-03-31
Filed2025-06-19
StandardIFRS
ConsolidatedYes
Data checks21 of 21 passed
Key figures · 157
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥438.3bn | 2024-04-01 → 2025-03-31 | Cons. | Revenue IFRS |
| Revenue | ¥410.1bn | 2023-04-01 → 2024-03-31 | Cons. | Revenue IFRS |
| Revenue | ¥426.7bn | 2022-04-01 → 2023-03-31d | Cons. | Revenue IFRS (5-year summary) |
| Revenue | ¥335.1bn | 2021-04-01 → 2022-03-31d | Cons. | Revenue IFRS (5-year summary) |
| Revenue | ¥297.2bn | 2020-04-01 → 2021-03-31d | Cons. | Revenue IFRS (5-year summary) |
| Operating income | ¥156.6bn | 2024-04-01 → 2025-03-31 | Cons. | Operating profit loss IFRS |
| Operating income | ¥153.3bn | 2023-04-01 → 2024-03-31 | Cons. | Operating profit loss IFRS |
| Profit before tax | ¥200.8bn | 2024-04-01 → 2025-03-31 | Cons. | Profit loss before tax IFRS |
| Profit before tax | ¥198.3bn | 2023-04-01 → 2024-03-31 | Cons. | Profit loss before tax IFRS |
| Profit before tax | ¥220.3bn | 2022-04-01 → 2023-03-31d | Cons. | Profit loss before tax IFRS (5-year summary) |
| Profit before tax | ¥126.3bn | 2021-04-01 → 2022-03-31d | Cons. | Profit loss before tax IFRS (5-year summary) |
| Profit before tax | ¥143.0bn | 2020-04-01 → 2021-03-31d | Cons. | Profit loss before tax IFRS (5-year summary) |
| Net income (owners) | ¥170.4bn | 2024-04-01 → 2025-03-31 | Cons. | Profit loss attributable to owners of parent IFRS |
| Net income (owners) | ¥162.0bn | 2023-04-01 → 2024-03-31 | Cons. | Profit loss attributable to owners of parent IFRS |
| Net income (owners) | ¥185.0bn | 2022-04-01 → 2023-03-31d | Cons. | Profit loss attributable to owners of parent IFRS (5-year summary) |
| Net income (owners) | ¥114.2bn | 2021-04-01 → 2022-03-31d | Cons. | Profit loss attributable to owners of parent IFRS (5-year summary) |
| Net income (owners) | ¥111.9bn | 2020-04-01 → 2021-03-31d | Cons. | Profit loss attributable to owners of parent IFRS (5-year summary) |
| Net income | ¥169.5bn | 2024-04-01 → 2025-03-31 | Cons. | Profit loss IFRS |
| Net income | ¥160.6bn | 2023-04-01 → 2024-03-31 | Cons. | Profit loss IFRS |
| Total assets | ¥1.54T | at 2025-03-31 | Cons. | Assets IFRS |
| Total assets | ¥1.42T | at 2024-03-31 | Cons. | Assets IFRS |
| Total assets | ¥1.31T | at 2023-03-31d | Cons. | Total assets IFRS (5-year summary) |
| Total assets | ¥1.15T | at 2022-03-31d | Cons. | Total assets IFRS (5-year summary) |
| Total assets | ¥999.0bn | at 2021-03-31d | Cons. | Total assets IFRS (5-year summary) |
| Total liabilities | ¥172.9bn | at 2025-03-31 | Cons. | Liabilities IFRS |
| Total liabilities | ¥164.4bn | at 2024-03-31 | Cons. | Liabilities IFRS |
| Net assets / equity | ¥1.36T | at 2025-03-31 | Cons. | Equity IFRS |
| Net assets / equity | ¥1.25T | at 2024-03-31 | Cons. | Equity IFRS |
| Net assets / equity | ¥1.12T | at 2023-03-31d | Cons. | Equity IFRS |
| Equity (owners) | ¥1.36T | at 2025-03-31 | Cons. | Equity attributable to owners of parent IFRS |
| Equity (owners) | ¥1.24T | at 2024-03-31 | Cons. | Equity attributable to owners of parent IFRS |
| Equity (owners) | ¥1.10T | at 2023-03-31d | Cons. | Equity attributable to owners of parent IFRS (5-year summary) |
| Equity (owners) | ¥975.7bn | at 2022-03-31d | Cons. | Equity attributable to owners of parent IFRS (5-year summary) |
| Equity (owners) | ¥846.1bn | at 2021-03-31d | Cons. | Equity attributable to owners of parent IFRS (5-year summary) |
| Cash & equivalents | ¥374.8bn | at 2025-03-31 | Cons. | Cash and cash equivalents IFRS |
| Cash & equivalents | ¥358.1bn | at 2024-03-31 | Cons. | Cash and cash equivalents IFRS |
| Cash & equivalents | ¥309.2bn | at 2023-03-31d | Cons. | Cash and cash equivalents IFRS |
| Cash & equivalents | ¥254.4bn | at 2022-03-31d | Cons. | Cash and cash equivalents IFRS (5-year summary) |
| Cash & equivalents | ¥276.2bn | at 2021-03-31d | Cons. | Cash and cash equivalents IFRS (5-year summary) |
| Operating cash flow | ¥195.5bn | 2024-04-01 → 2025-03-31 | Cons. | Net cash provided by used in operating activities IFRS |
| Operating cash flow | ¥154.3bn | 2023-04-01 → 2024-03-31 | Cons. | Net cash provided by used in operating activities IFRS |
| Operating cash flow | ¥177.9bn | 2022-04-01 → 2023-03-31d | Cons. | Cash flows from used in operating activities IFRS (5-year summary) |
| Operating cash flow | ¥102.1bn | 2021-04-01 → 2022-03-31d | Cons. | Cash flows from used in operating activities IFRS (5-year summary) |
| Operating cash flow | ¥109.0bn | 2020-04-01 → 2021-03-31d | Cons. | Cash flows from used in operating activities IFRS (5-year summary) |
| Investing cash flow | −¥116.1bn | 2024-04-01 → 2025-03-31 | Cons. | Net cash provided by used in investing activities IFRS |
| Investing cash flow | ¥5.9bn | 2023-04-01 → 2024-03-31 | Cons. | Net cash provided by used in investing activities IFRS |
| Investing cash flow | −¥48.3bn | 2022-04-01 → 2023-03-31d | Cons. | Cash flows from used in investing activities IFRS (5-year summary) |
| Investing cash flow | −¥96.2bn | 2021-04-01 → 2022-03-31d | Cons. | Cash flows from used in investing activities IFRS (5-year summary) |
| Investing cash flow | −¥5.3bn | 2020-04-01 → 2021-03-31d | Cons. | Cash flows from used in investing activities IFRS (5-year summary) |
| Financing cash flow | −¥64.9bn | 2024-04-01 → 2025-03-31 | Cons. | Net cash provided by used in financing activities IFRS |
| Financing cash flow | −¥126.9bn | 2023-04-01 → 2024-03-31 | Cons. | Net cash provided by used in financing activities IFRS |
| Financing cash flow | −¥84.1bn | 2022-04-01 → 2023-03-31d | Cons. | Cash flows from used in financing activities IFRS (5-year summary) |
| Financing cash flow | −¥36.6bn | 2021-04-01 → 2022-03-31d | Cons. | Cash flows from used in financing activities IFRS (5-year summary) |
| Financing cash flow | −¥43.9bn | 2020-04-01 → 2021-03-31d | Cons. | Cash flows from used in financing activities IFRS (5-year summary) |
| EPS (basic) | ¥200.36 | 2024-04-01 → 2025-03-31 | Cons. | Basic earnings loss per share IFRS |
| EPS (basic) | ¥186.17 | 2023-04-01 → 2024-03-31 | Cons. | Basic earnings loss per share IFRS |
| EPS (basic) | ¥207.1 | 2022-04-01 → 2023-03-31d | Cons. | Basic earnings loss per share IFRS (5-year summary) |
| EPS (basic) | ¥126.25 | 2021-04-01 → 2022-03-31d | Cons. | Basic earnings loss per share IFRS (5-year summary) |
| EPS (basic) | ¥121.68 | 2020-04-01 → 2021-03-31d | Cons. | Basic earnings loss per share IFRS (5-year summary) |
| EPS (diluted) | ¥200.29 | 2024-04-01 → 2025-03-31 | Cons. | Diluted earnings loss per share IFRS |
| EPS (diluted) | ¥186.11 | 2023-04-01 → 2024-03-31 | Cons. | Diluted earnings loss per share IFRS |
| EPS (diluted) | ¥207.03 | 2022-04-01 → 2023-03-31d | Cons. | Diluted earnings loss per share IFRS (5-year summary) |
| EPS (diluted) | ¥126.21 | 2021-04-01 → 2022-03-31d | Cons. | Diluted earnings loss per share IFRS (5-year summary) |
| EPS (diluted) | ¥121.63 | 2020-04-01 → 2021-03-31d | Cons. | Diluted earnings loss per share IFRS (5-year summary) |
| Net assets per share | ¥1,600.68 | at 2025-03-31 | Cons. | Equity to asset ratio IFRS (5-year summary) |
| Net assets per share | ¥1,452.22 | at 2024-03-31 | Cons. | Equity to asset ratio IFRS (5-year summary) |
| Net assets per share | ¥1,245.92 | at 2023-03-31d | Cons. | Equity to asset ratio IFRS (5-year summary) |
| Net assets per share | ¥1,078.74 | at 2022-03-31d | Cons. | Equity to asset ratio IFRS (5-year summary) |
| Net assets per share | ¥935.56 | at 2021-03-31d | Cons. | Equity to asset ratio IFRS (5-year summary) |
| Equity ratio | 88.7% | at 2025-03-31 | Cons. | Ratio of owners equity to gross assets IFRS (5-year summary) |
| Equity ratio | 87.2% | at 2024-03-31 | Cons. | Ratio of owners equity to gross assets IFRS (5-year summary) |
| Equity ratio | 83.9% | at 2023-03-31d | Cons. | Ratio of owners equity to gross assets IFRS (5-year summary) |
| Equity ratio | 84.8% | at 2022-03-31d | Cons. | Ratio of owners equity to gross assets IFRS (5-year summary) |
| Equity ratio | 84.7% | at 2021-03-31d | Cons. | Ratio of owners equity to gross assets IFRS (5-year summary) |
| ROE | 13.1% | 2024-04-01 → 2025-03-31 | Cons. | Rate of return on equity IFRS (5-year summary) |
| ROE | 13.9% | 2023-04-01 → 2024-03-31 | Cons. | Rate of return on equity IFRS (5-year summary) |
| ROE | 17.8% | 2022-04-01 → 2023-03-31d | Cons. | Rate of return on equity IFRS (5-year summary) |
| ROE | 12.5% | 2021-04-01 → 2022-03-31d | Cons. | Rate of return on equity IFRS (5-year summary) |
| ROE | 13.9% | 2020-04-01 → 2021-03-31d | Cons. | Rate of return on equity IFRS (5-year summary) |
| Employees | 4,955 | at 2025-03-31 | Cons. | Number of employees |
| Employees | 4,959 | at 2024-03-31 | Cons. | Number of employees |
| Employees | 5,680 | at 2023-03-31d | Cons. | Number of employees |
| Employees | 5,693 | at 2022-03-31d | Cons. | Number of employees |
| Employees | 5,485 | at 2021-03-31d | Cons. | Number of employees |
| Revenue | ¥363.3bn | 2024-04-01 → 2025-03-31 | Standalone | Net sales |
| Revenue | ¥345.8bn | 2023-04-01 → 2024-03-31 | Standalone | Net sales |
| Revenue | ¥369.5bn | 2022-04-01 → 2023-03-31d | Standalone | Net sales (5-year summary) |
| Revenue | ¥285.9bn | 2021-04-01 → 2022-03-31d | Standalone | Net sales (5-year summary) |
| Revenue | ¥261.0bn | 2020-04-01 → 2021-03-31d | Standalone | Net sales (5-year summary) |
| Operating income | ¥114.4bn | 2024-04-01 → 2025-03-31 | Standalone | Operating income |
| Operating income | ¥109.0bn | 2023-04-01 → 2024-03-31 | Standalone | Operating income |
| Ordinary income | ¥109.1bn | 2024-04-01 → 2025-03-31 | Standalone | Ordinary income |
| Ordinary income | ¥258.6bn | 2023-04-01 → 2024-03-31 | Standalone | Ordinary income |
| Ordinary income | ¥135.0bn | 2022-04-01 → 2023-03-31d | Standalone | Ordinary income loss (5-year summary) |
| Ordinary income | ¥100.9bn | 2021-04-01 → 2022-03-31d | Standalone | Ordinary income loss (5-year summary) |
| Ordinary income | ¥81.7bn | 2020-04-01 → 2021-03-31d | Standalone | Ordinary income loss (5-year summary) |
| Profit before tax | ¥107.7bn | 2024-04-01 → 2025-03-31 | Standalone | Income before income taxes |
| Profit before tax | ¥281.3bn | 2023-04-01 → 2024-03-31 | Standalone | Income before income taxes |
| Net income | ¥86.9bn | 2024-04-01 → 2025-03-31 | Standalone | Profit loss |
| Net income | ¥253.1bn | 2023-04-01 → 2024-03-31 | Standalone | Profit loss |
| Net income | ¥107.4bn | 2022-04-01 → 2023-03-31d | Standalone | Net income loss (5-year summary) |
| Net income | ¥90.3bn | 2021-04-01 → 2022-03-31d | Standalone | Net income loss (5-year summary) |
| Net income | ¥32.2bn | 2020-04-01 → 2021-03-31d | Standalone | Net income loss (5-year summary) |
| Total assets | ¥941.2bn | at 2025-03-31 | Standalone | Assets |
| Total assets | ¥840.6bn | at 2024-03-31 | Standalone | Assets |
| Total assets | ¥768.1bn | at 2023-03-31d | Standalone | Total assets (5-year summary) |
| Total assets | ¥730.1bn | at 2022-03-31d | Standalone | Total assets (5-year summary) |
| Total assets | ¥617.1bn | at 2021-03-31d | Standalone | Total assets (5-year summary) |
| Total liabilities | ¥149.4bn | at 2025-03-31 | Standalone | Liabilities |
| Total liabilities | ¥91.1bn | at 2024-03-31 | Standalone | Liabilities |
| Net assets / equity | ¥791.8bn | at 2025-03-31 | Standalone | Net assets |
| Net assets / equity | ¥749.5bn | at 2024-03-31 | Standalone | Net assets |
| Net assets / equity | ¥612.9bn | at 2023-03-31d | Standalone | Net assets |
| Net assets / equity | ¥590.4bn | at 2022-03-31d | Standalone | Net assets (5-year summary) |
| Net assets / equity | ¥536.4bn | at 2021-03-31d | Standalone | Net assets (5-year summary) |
| Cash and deposits | ¥295.7bn | at 2025-03-31 | Standalone | Cash and deposits |
| Cash and deposits | ¥196.2bn | at 2024-03-31 | Standalone | Cash and deposits |
| EPS (basic) | ¥101.12 | 2024-04-01 → 2025-03-31 | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥287.79 | 2023-04-01 → 2024-03-31 | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥119.51 | 2022-04-01 → 2023-03-31d | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥99.8 | 2021-04-01 → 2022-03-31d | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥35.01 | 2020-04-01 → 2021-03-31d | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (diluted) | ¥101.09 | 2024-04-01 → 2025-03-31 | Standalone | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥287.69 | 2023-04-01 → 2024-03-31 | Standalone | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥119.47 | 2022-04-01 → 2023-03-31d | Standalone | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥99.77 | 2021-04-01 → 2022-03-31d | Standalone | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥34.99 | 2020-04-01 → 2021-03-31d | Standalone | Diluted earnings per share (5-year summary) |
| Dividend per share | ¥118 | 2024-04-01 → 2025-03-31 | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥160 | 2023-04-01 → 2024-03-31 | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥135 | 2022-04-01 → 2023-03-31d | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥115 | 2021-04-01 → 2022-03-31d | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥108 | 2020-04-01 → 2021-03-31d | Standalone | Dividend paid per share (5-year summary) |
| Net assets per share | ¥920.78 | at 2025-03-31 | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥871.75 | at 2024-03-31 | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥686.88 | at 2023-03-31d | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥652.53 | at 2022-03-31d | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥592.83 | at 2021-03-31d | Standalone | Net assets per share (5-year summary) |
| Equity ratio | 84.1% | at 2025-03-31 | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 89.1% | at 2024-03-31 | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 79.8% | at 2023-03-31d | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 80.8% | at 2022-03-31d | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 86.9% | at 2021-03-31d | Standalone | Equity to asset ratio (5-year summary) |
| ROE | 11.3% | 2024-04-01 → 2025-03-31 | Standalone | Rate of return on equity (5-year summary) |
| ROE | 37.2% | 2023-04-01 → 2024-03-31 | Standalone | Rate of return on equity (5-year summary) |
| ROE | 17.9% | 2022-04-01 → 2023-03-31d | Standalone | Rate of return on equity (5-year summary) |
| ROE | 16.0% | 2021-04-01 → 2022-03-31d | Standalone | Rate of return on equity (5-year summary) |
| ROE | 6.0% | 2020-04-01 → 2021-03-31d | Standalone | Rate of return on equity (5-year summary) |
| Shares issued | 889,632,195 | at 2025-03-31 | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 307,386,165 | at 2024-03-31 | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 307,386,165 | at 2023-03-31d | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 311,586,165 | at 2022-03-31d | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 311,586,165 | at 2021-03-31d | Standalone | Total number of issued shares (5-year summary) |
| Employees | 2,129 | at 2025-03-31 | Standalone | Number of employees |
| Employees | 2,117 | at 2024-03-31 | Standalone | Number of employees |
| Employees | 2,458 | at 2023-03-31d | Standalone | Number of employees |
| Employees | 2,510 | at 2022-03-31d | Standalone | Number of employees |
| Employees | 2,589 | at 2021-03-31d | Standalone | Number of employees |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
All source rows · 1,674
| Item | Context | Value | Unit |
|---|---|---|---|
| Independent auditors report consolidated (text) | FilingDateInstant | Text · Plus | |
| Audit firm1 consolidated | FilingDateInstant | Original text (Japanese)EY新日本有限責任監査法人 | |
| Cpa1 audit firm1 consolidated | FilingDateInstant | Original text (Japanese)北池 晃一郎 | |
| Cpa2 audit firm1 consolidated | FilingDateInstant | Original text (Japanese)中澤 直規 | |
| Key audit matters consolidated (text) | FilingDateInstant | Text · Plus | |
| Overview kam consolidated (text) | FilingDateInstant | Text · Plus | |
| Short description kam consolidated | FilingDateInstant_Row1Member | Original text (Japanese)非上場株式（ViiV Healthcare Ltd.）の公正価値測定 | |
| Description including reason kam consolidated (text) | FilingDateInstant_Row1Member | Text · Plus | |
| Reference kam consolidated | FilingDateInstant_Row1Member | Original text (Japanese)「注記17. その他の金融資産」 | |
| Reference2 kam consolidated | FilingDateInstant_Row1Member | Original text (Japanese)「注記2. 作成の基礎」 | |
| Reference3 kam consolidated | FilingDateInstant_Row1Member | Original text (Japanese)「注記30. 金融商品」 | |
| Auditors response kam consolidated (text) | FilingDateInstant_Row1Member | Text · Plus | |
| Short description kam consolidated | FilingDateInstant_Row2Member | Original text (Japanese)Tetra Therapeutics Inc.の企業結合から識別した無形資産（仕掛研究開発資産）の評価 | |
| Description including reason kam consolidated (text) | FilingDateInstant_Row2Member | Text · Plus | |
| Reference kam consolidated | FilingDateInstant_Row2Member | Original text (Japanese)注記2. 作成の基礎 | |
| Auditors response kam consolidated (text) | FilingDateInstant_Row2Member | Text · Plus | |
| Other information consolidated (text) | FilingDateInstant | Text · Plus | |
| Fee related information consolidated (text) | FilingDateInstant | Text · Plus | |
| Independent auditors report non consolidated (text) | FilingDateInstant | Text · Plus | |
| Audit firm1 non consolidated | FilingDateInstant | Original text (Japanese)EY新日本有限責任監査法人 | |
| Cpa1 audit firm1 non consolidated | FilingDateInstant | Original text (Japanese)北池 晃一郎 | |
| Cpa2 audit firm1 non consolidated | FilingDateInstant | Original text (Japanese)中澤 直規 | |
| Key audit matters non consolidated (text) | FilingDateInstant | Text · Plus | |
| Overview kam non consolidated (text) | FilingDateInstant | Text · Plus | |
| Short description kam non consolidated | FilingDateInstant_Row1Member | Original text (Japanese)関係会社株式(Tetra Therapeutics Inc.)の評価 | |
| Description including reason kam non consolidated (text) | FilingDateInstant_Row1Member | Text · Plus | |
| Reference kam non consolidated | FilingDateInstant_Row1Member | Original text (Japanese)注記事項(重要な会計方針) | |
| Reference2 kam non consolidated | FilingDateInstant_Row1Member | Original text (Japanese)注記事項(重要な会計上の見積り) | |
| Auditors response kam non consolidated (text) | FilingDateInstant_Row1Member | Text · Plus | |
| Other information non consolidated (text) | FilingDateInstant | Text · Plus | |
| Fee related information non consolidated (text) | FilingDateInstant | Text · Plus | |
| Number of submission | FilingDateInstant | 1 | |
| Revenue IFRS (5-year summary) | Prior4YearDuration | 297177000000 | JPY |
| Revenue IFRS (5-year summary) | Prior3YearDuration | 335138000000 | JPY |
| Revenue IFRS (5-year summary) | Prior2YearDuration | 426684000000 | JPY |
| Revenue IFRS (5-year summary) | Prior1YearDuration | 410073000000 | JPY |
| Revenue IFRS (5-year summary) | CurrentYearDuration | 438268000000 | JPY |
| Revenue including profit from license transfer IFRS (key data) | Prior4YearDuration | 297177000000 | JPY |
| Revenue including profit from license transfer IFRS (key data) | Prior3YearDuration | 335138000000 | JPY |
| Revenue including profit from license transfer IFRS (key data) | Prior2YearDuration | 426684000000 | JPY |
| Revenue including profit from license transfer IFRS (key data) | Prior1YearDuration | 435081000000 | JPY |
| Revenue including profit from license transfer IFRS (key data) | CurrentYearDuration | 438268000000 | JPY |
| Profit loss before tax IFRS (5-year summary) | Prior4YearDuration | 143018000000 | JPY |
| Profit loss before tax IFRS (5-year summary) | Prior3YearDuration | 126268000000 | JPY |
| Profit loss before tax IFRS (5-year summary) | Prior2YearDuration | 220332000000 | JPY |
| Profit loss before tax IFRS (5-year summary) | Prior1YearDuration | 198283000000 | JPY |
| Profit loss before tax IFRS (5-year summary) | CurrentYearDuration | 200750000000 | JPY |
| Profit loss attributable to owners of parent IFRS (5-year summary) | Prior4YearDuration | 111858000000 | JPY |
| Profit loss attributable to owners of parent IFRS (5-year summary) | Prior3YearDuration | 114185000000 | JPY |
| Profit loss attributable to owners of parent IFRS (5-year summary) | Prior2YearDuration | 184965000000 | JPY |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 21 of 21 passed
| balance sheet identity | pass rounding |
| balance sheet identity | pass |
| balance sheet identity | pass |
| balance sheet identity | pass rounding |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |